Imaging of Neuroendocrine Prostatic Carcinoma.
Ahmed TaherCorey T JensenSireesha YedururiDevaki Shilpa SurasiSilvana C FariaTharakeshwar K BathalaBilal MujtabaPriya BhosaleNicolaus Wagner-BartakAjaykumar C MoraniPublished in: Cancers (2021)
Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that typically has a high metastatic potential and poor prognosis in comparison to the adenocarcinoma subtype. Although it can arise de novo, NEPC much more commonly occurs as a mechanism of treatment resistance during therapy for conventional prostatic adenocarcinoma, the latter is also termed as castration-resistant prostate cancer (CRPC). The incidence of NEPC increases after hormonal therapy and they represent a challenge, both in the radiological and pathological diagnosis, as well as in the clinical management. This article provides a comprehensive imaging review of prostatic neuroendocrine tumors.
Keyphrases
- radical prostatectomy
- prostate cancer
- poor prognosis
- neuroendocrine tumors
- squamous cell carcinoma
- benign prostatic hyperplasia
- high resolution
- long non coding rna
- small cell lung cancer
- locally advanced
- risk factors
- type diabetes
- metabolic syndrome
- stem cells
- mass spectrometry
- replacement therapy
- mesenchymal stem cells
- fluorescence imaging
- radiation therapy
- bone marrow
- adipose tissue
- insulin resistance